European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors

CPHI India reports surge in exhibitor numbers

Modernization and supply chain diversity drive new growth

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex

USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency

Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS

EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility

The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr

Q2 FY25 Total Income was at Rs. 85.4 crore

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr

Hospital business revenues increase 13.9% to Rs. 1,655 crore

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024